Stay updated on PATHWay Study: Adjuvant Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Locations section now consolidates the study sites under Georgia, Illinois, and Pennsylvania, replacing separate location pages. The HHS Vulnerability Disclosure link has been removed.
    Difference
    0.5%
    Check dated 2025-12-22T22:26:02.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.2 replacing v3.3.1, and the study details appear unchanged aside from the revision label. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T11:51:45.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.1, replacing the previous Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-24T11:50:40.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    Results status updated from 'No Results Posted' to 'Results Submitted'; the government funding/operating status notice has been removed.
    Difference
    0.5%
    Check dated 2025-11-17T06:19:54.000Z thumbnail image
  8. Check
    63 days ago
    Change Detected
    Summary
    The PATHWay study page content is unchanged with respect to study design, eligibility criteria, and reported outcomes. No new sections or substantive data were observed in the current view.
    Difference
    0.4%
    Check dated 2025-11-03T00:54:27.000Z thumbnail image
  9. Check
    92 days ago
    Change Detected
    Summary
    Major changes are the addition of a government-operating-status notice, new upcoming dates, and the upgrade to revision v3.2.0, while several mid-2025 dates and the older revision v3.1.0 were removed. Core content remains largely the same.
    Difference
    4%
    Check dated 2025-10-05T08:06:12.000Z thumbnail image

Stay in the know with updates to PATHWay Study: Adjuvant Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.